Product Information
27829-1-PBS targets VSIG4 in WB, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag27214 Product name: Recombinant human VSIG4 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 305-399 aa of BC010525 Sequence: MLCRKTSQQEHVYEAARAHAREANDSGETMRVAIFASGCSSDEPTSQNLGNNYSDEPCIGQEYQIIAQINGNYARLLDTVPLDYEFLATEGKSVC Predict reactive species |
| Full Name | V-set and immunoglobulin domain containing 4 |
| Calculated Molecular Weight | 399 aa, 44 kDa |
| Observed Molecular Weight | 44 kDa |
| GenBank Accession Number | BC010525 |
| Gene Symbol | VSIG4 |
| Gene ID (NCBI) | 11326 |
| RRID | AB_3742260 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9Y279 |
| Storage Buffer | PBS only, pH 7.3. |
| Storage Conditions | Store at -80°C. |
Background Information
V-set and immunoglobulin domain-containing 4 (VSIG4) is a complement receptor of the immunoglobulin superfamily (CRIg) that is specifically expressed in resting tissue-resident macrophages . Notably, CRIg is expressed in monocyte-derived macrophages but not in human and mouse monocytes. VSIG4 can suppress T cell proliferation and promote Foxp3+ regulatory T cell (Tregs) differentiation by binding an unidentified receptor on T cells . VSIG4 has been implicated in a variety of diseases, particularly those involving immune dysregulation and inflammation, such as non-alcoholic steatohepatitis, rheumatoid arthritis, and obesity-related metabolic disorders . Recently, VSIG4+ tumor-associated macrophages (TAMs) have been identified as a specific subset that infiltrates aggressive cancers, including anaplastic thyroid cancer (ATC). (PMID: 37153746,PMID: 39920772)
